Advertisement
Singapore markets close in 7 hours 40 minutes
  • Straits Times Index

    3,278.59
    -9.16 (-0.28%)
     
  • Nikkei

    37,652.27
    +23.79 (+0.06%)
     
  • Hang Seng

    17,284.54
    0.00 (0.00%)
     
  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     
  • Bitcoin USD

    64,095.11
    -353.79 (-0.55%)
     
  • CMC Crypto 200

    1,387.95
    +5.37 (+0.39%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • Dow

    38,085.80
    -375.12 (-0.98%)
     
  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     
  • Gold

    2,340.00
    -2.50 (-0.11%)
     
  • Crude Oil

    83.92
    +0.35 (+0.42%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • FTSE Bursa Malaysia

    1,566.94
    -2.31 (-0.15%)
     
  • Jakarta Composite Index

    7,155.29
    -7,174.53 (-50.07%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Is Inovio Pharmaceuticals Primed For a Comeback?

Is Inovio Pharmaceuticals Primed For a Comeback?

It seems like a long time ago that Inovio Pharmaceuticals (NASDAQ: INO) was considered a leader in the race to develop an effective coronavirus vaccine. Unsurprisingly, investors mostly gave up on Inovio, and its shares have lost more than half their value in the past 12 months. Inovio hasn't given up on its COVID-19 vaccine program, but the biotech can't conduct a phase 3 clinical trial for INO-4800 in the U.S. at the moment.